Physician profile
Chadd Todd
NPI 1912369612
$1,642.88
in general payments reported to CMS, 2019-2025
14 companies · $811 in 2025
The $811 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $13.48 · 2021: $34.32 · 2022: $78.43 · 2023: $121 · 2024: $406 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.31 | 2022-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $259.62 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $232.87 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $174.65 | 2019-2025 | |
| Lilly USA, LLC | $143.37 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $116.71 | 2019 | |
| Exact Sciences Corporation | $28.98 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $27.60 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.26 | 2025 | Fanapt |
| Abbott Laboratories | $22.18 | 2023 | Freestyle Libre |
| Tolmar, INC. | $16.39 | 2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $16.26 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.24 | 2025 | Recorlev |
| Dynavax Technologies Corporation | $8.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadd Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.